STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
Eli Lilly's investigational combination therapy involving their blockbuster GLP-1 drug Zepbound and amylin hormone-targeting candidate eloralintide showed promising results in a mid-stage study. When tested in people with obesity and type 2 diabetes, the combination therapy led to a significant weight loss of 23.3% after 48 weeks, as reported at the European Association for the Study of Diabetes annual meeting.
This weight loss surpassed the results obtained from individuals taking only Zepbound (14.8%) and those taking the highest dose of eloralintide alone (11.1%). The findings were particularly noteworthy, as patients with diabetes typically experience less weight loss compared to those without diabetes.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
